Inside the Piramal Pharma Sustainability Report: Our Progress Toward Responsible Growth

The Piramal Pharma Sustainability Report is structured around four strategic pillars: Business Resilience, Quality and Excellence, Responsible Operations, and Stakeholder Centricity. Together, these pillars support 12 defined sustainability focus areas and address 17 material topics identified through structured stakeholder engagement, translated into more than 50 specific, time-bound targets.

The report has been prepared in line with the Global Reporting Initiative Universal Standards 2021 and aligned with the United Nations Sustainable Development Goals, with key disclosures independently assured by DNV Business Assurance India. Among the year's standout figures: a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline, 41% of total energy consumption sourced from renewables, zero fatalities over the last five years, and ₹8.98 crore invested in CSR programmes that reached approximately 1.8 million people. These outcomes reflect a business that is treating sustainability not as a compliance exercise, but as a driver of long-term value.

Piramal Pharma's approach to corporate social responsibility is guided by its founding philosophy of "Doing Well and Doing Good." The company's CSR agenda is overseen by a dedicated Board Committee responsible for setting policy, monitoring programme impact, and ensuring compliance in fund utilisation.

This year, CSR spending reached ₹8.98 crore, supporting health and education programmes across 112 aspirational districts and positively impacting close to 1.8 million people through the work of the Piramal Foundation. This reflects a belief that runs through the report: that business success should be measured not only in financial terms, but in the tangible difference it makes to the communities in which the company operates.

Governance discipline reinforces this commitment. All Board members participated in sessions focused on sustainability, compliance, and risk management, and the company reported zero corruption incidents alongside 100% workforce training on its Code of Conduct underscoring that social responsibility and ethical governance go hand in hand.

Several metrics stand out as markers of progress across the company's four sustainability pillars:

• Environmental performance: 22.6% lower GHG emissions versus the FY2022 baseline, 41% renewable energy share, and over 6,520 saplings planted, helping maintain more than 30% green cover across Indian operations.
• Governance strength: 50% of the Board comprising Independent Directors, 30% women's representation on the Board, and zero cases of data breaches reported during the year.
• Quality and operational trust: 38 successful regulatory inspections, 209 successful customer audits, and zero Official Action Indications across all USFDA inspections.
• Workforce and safety: Zero fatalities over the last five years, 100% completion of ESG training by employees, and 20.1% representation of women in the global workforce.
• External recognition: An EcoVadis score placing the company in the Bronze Medal category (78th percentile) and an S&P Global ESG score of 63, alongside multiple industry awards for safety, quality, and workplace culture.

Collectively, these figures illustrate a company making steady, verifiable progress rather than relying on broad commitments alone.